Rate administer each 25 mg slowly over at least 1015

● Rate: Administer each 25 mg slowly, over at least 10–15 min (maximum rate = 25 mg/min).
Rapid administration may produce a transient fall in BP.
Patient/Family Teaching
● Review dose schedule with patient. If medication is ordered regularly and a dose is missed,
take as soon as remembered unless time for next dose. Pedi: Caution caregivers to use only
the measuring device accompanying the liquid medication and not to use household measuring
devices.
○ May cause drowsiness. Caution patient to avoid driving or other activities requiring
alertness until response to medication is known.
○ Advise patient that frequent mouth rinses, good oral hygiene, and sugarless gum or
candy may decrease dry mouth. Health care professional should be notified if dry
mouth persists >2 wk.
○ Caution patient to use sunscreen and protective clothing to prevent photosensitivity
reactions.
○ Advise patient to change positions slowly to minimize orthostatic hypotension.
Protect from falls. Geri: Geriatric patients are at increased risk.
○ Caution patient to avoid concurrent use of alcohol and other CNS depressants with
this medication.
○ Instruct patient to notify health care professional if sore throat, fever, jaundice, or
uncontrolled movements are noted.
● Motion Sickness: When used as prophylaxis for motion sickness, advise patient to take
medication at least 30 min and preferably 1–2 hr before exposure to conditions that may cause
motion sickness.
Evaluation/Desired Outcomes
● Relief from allergic symptoms.
● Prevention of motion sickness.
● Sedation.
● Relief from nausea and vomiting.
*clopidogrel
General
Genetic Implications:
Pronunciation:
kloh- pid -oh-grel
Trade Name(s)
● *Plavix

Ther. Class.
antiplatelet agents
Pharm. Class.
platelet aggregation inhibitors
Indications
● Acute coronary syndrome (ST-segment elevation MI, non-ST-segment
elevation MI, or unstable angina).
● Patients with established peripheral arterial disease, recent MI, or
recent stroke.
Action
Inhibits platelet aggregation by irreversibly inhibiting the binding of ATP to platelet
receptors.
Therapeutic Effect(s):
Reduction in risk of MI and stroke.
Pharmacokinetics
Absorption: Well absorbed following oral administration; rapidly metabolized to
an active antiplatelet compound. Parent drug has no antiplatelet activity.
Distribution: Unknown.
Protein Binding: Clopidogrel– 98%; active metabolite– 94%.
Metabolism and Excretion: Rapidly and extensively converted by the liver
(CYP2C19) to its active metabolite, which is then eliminated 50% in urine and 45%
in feces; 2% of Whites, 4% of Blacks, and 14% of Asians have CYP2C19
genotype that results in reduced metabolism of clopidogrel (poor metabolizers)
into its active metabolite (may result in ↓ antiplatelet effects).
Half-life: 6 hr (active metabolite 30 min).
TIME/ACTION PROFILE (effects on platelet function)

PO within 24 hr 3–7 days 5 days†
†Following discontinuation.
Contraindication/Precautions
Contraindicated in:
● Hypersensitivity to clopidogrel or prasugrel;
● Pathologic bleeding (peptic ulcer, intracranial hemorrhage);
●